Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa
PLOS One · 2026
DOI: 10.1371/journal.pone.0336561 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Thomas Wilkinson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Unit, School of Public Health, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Levofloxacin, Health Care Costs. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, UNITAID, Joint Global Health Trials.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Tuberculosis (TB) preventive treatment (TPT) is a core component of TB control. Levofloxacin was recently recommended by the World Health Organization as TPT in children exposed to multidrug-resistant tuberculosis (MDR-TB). However, the affordability and feasibility of TPT provision for governments, health services, individual households and global donors is uncertain.
Methods
This costing analysis used empirical data collected alongside the TB-CHAMP clinical trial which investigated levofloxacin TPT in children exposed to MDR-TB in South Africa. We modelled the societal (health system and household) cost of levofloxacin TPT, other potential future (but not currently recommended) MDR-TB exposure TPT options and compared with drug-susceptible TPT options in children and adolescents under 15 years old. We modelled costs across 12 different medicine and formulation options for 11 paediatric dosing weight-bands using TB-CHAMP and household survey data, with national and international procurement medicine pricing.
Results
Total societal costs of providing levofloxacin TPT and its monitoring per child were US$252 (0- < 5 years) and US$256 (5- < 15-years) and had comparable costs to drug-susceptible TPT regimens when using Global Drug Facility pricing. Pharmaceutical costs for a course of TPT using child-friendly formulations in children
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Economics Unit, School of Public Health, University of Cape Town, Cape Town, South Africa.
- Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town, South Africa.
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
- Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
- Wits Research Health Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- THINK, THINK South Africa, Durban, South Africa.
ORCID-Profile: Thomas Wilkinson, Suereta Fortuin, H Simon Schaaf, Lee Fairlie
Förderung
- Wellcome Trust
- UNITAID
- Joint Global Health Trials
- South African Medical Research Council
- MRC
Zitieren
APA
Wilkinson, T., Fortuin, S., Hesseling, A. C., Schaaf, H. S., Duong, T., Gibb, D. M., Purchase, S. E., Fairlie, L., Staples, S., Martinson, N., Sinanovic, E., & Seddon, J. A. (2026). Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa. PLOS One. https://doi.org/10.1371/journal.pone.0336561
Vancouver
Wilkinson T, Fortuin S, Hesseling AC, Schaaf HS, Duong T, Gibb DM, et al. Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa. PLOS One. 2026. doi:10.1371/journal.pone.0336561
BibTeX
@article{Wilkinson2026,
author = {Wilkinson, Thomas and Fortuin, Suereta and Hesseling, Anneke C and Schaaf, H Simon and Duong, Trinh and Gibb, Diana M and Purchase, Susan E and Fairlie, Lee and Staples, Suzanne and Martinson, Neil and Sinanovic, Edina and Seddon, James A},
title = {Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0336561}
}
EUVIMED